Alberto Revelli1, Gianluca Gennarelli2, Marta Sestero2, Stefano Canosa2, Andrea Carosso2, Francesca Salvagno2, Giulia Pittatore2, Claudia Filippini3, Chiara Benedetto2. 1. Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy. alberto.revelli@unito.it. 2. Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy. 3. Clinical Statistics, Department of Surgical Sciences, University of Torino, Corso Bramante 88, Turin, Italy.
Abstract
OBJECTIVE: To assess whether corifollitropin-α (CFα) late-start administration (day 4) and standard administration (day 2) can obtain similar oocyte yield and live birth rate. STUDY DESIGN: A randomized controlled trial. SETTING:University Hospital IVF Unit. PATIENTS: One hundred thirteen women undergoing IVF. INTERVENTIONS:Patients distributed in three subgroups (expected poor, normal, or high responders to FSH) were randomized into two treatment arms: (a) CFα late-start: CFα on day 4 + GnRH antagonist from day 8 + (when needed) recFSH from day 11; (b) CFα standard start: CFα on day 2 + GnRH antagonist from day 6 + (when needed) recFSH from day 9. IVF or ICSI was performed as indicated. RESULTS: Considering the whole study group, the late-start regimen obtained comparable oocyte yield (8.9 ± 5.6 vs. 8.8 ± 6.2; p = n.s.), cPR/started cycle (25% vs. 31.6%, p = n.s.), and cumulative live birth rate (LBR)/ovum pickup (OPU) (29.2% vs. 37.7%, p = n.s.) than the standard regimen. The outcome of the two regimens was comparable in the two subgroups of high and normal responders. Differently, in poor responders, oocyte yield was similar, but LBR/OPU was significantly lower with late-start CFα administration that caused 40% cancellation rate due to monofollicular response. ROC curves showed that the threshold AMH levels associated with cycle cancellation were 0.6 ng/ml for late-start regimen and 0.2 ng/ml for standard regimen. CONCLUSION:CFα may be administered on either day 2 or day 4 to patients with expected high or normal response to FSH without compromising oocyte yield and/or live birth rate. Differently, late-start administration is not advisable for expected poor responders with AMH ≤ 0.6 ng/ml. TRIAL REGISTRATION: NCT03816670.
RCT Entities:
OBJECTIVE: To assess whether corifollitropin-α (CFα) late-start administration (day 4) and standard administration (day 2) can obtain similar oocyte yield and live birth rate. STUDY DESIGN: A randomized controlled trial. SETTING: University Hospital IVF Unit. PATIENTS: One hundred thirteen women undergoing IVF. INTERVENTIONS:Patients distributed in three subgroups (expected poor, normal, or high responders to FSH) were randomized into two treatment arms: (a) CFα late-start: CFα on day 4 + GnRH antagonist from day 8 + (when needed) recFSH from day 11; (b) CFα standard start: CFα on day 2 + GnRH antagonist from day 6 + (when needed) recFSH from day 9. IVF or ICSI was performed as indicated. RESULTS: Considering the whole study group, the late-start regimen obtained comparable oocyte yield (8.9 ± 5.6 vs. 8.8 ± 6.2; p = n.s.), cPR/started cycle (25% vs. 31.6%, p = n.s.), and cumulative live birth rate (LBR)/ovum pickup (OPU) (29.2% vs. 37.7%, p = n.s.) than the standard regimen. The outcome of the two regimens was comparable in the two subgroups of high and normal responders. Differently, in poor responders, oocyte yield was similar, but LBR/OPU was significantly lower with late-start CFα administration that caused 40% cancellation rate due to monofollicular response. ROC curves showed that the threshold AMH levels associated with cycle cancellation were 0.6 ng/ml for late-start regimen and 0.2 ng/ml for standard regimen. CONCLUSION: CFα may be administered on either day 2 or day 4 to patients with expected high or normal response to FSH without compromising oocyte yield and/or live birth rate. Differently, late-start administration is not advisable for expected poor responders with AMH ≤ 0.6 ng/ml. TRIAL REGISTRATION: NCT03816670.
Entities:
Keywords:
Controlled ovarian stimulation; Corifollitropin α; Gonadotropins; In vitro fertilization; Live birth rate; Mild ovarian stimulation; Pregnancy rate
Authors: Esther Mew Heijnen; Marinus Jc Eijkemans; Cora De Klerk; Suzanne Polinder; Nicole Gm Beckers; Ellen R Klinkert; Frank J Broekmans; Jan Passchier; Egbert R Te Velde; Nick S Macklon; Bart Cjm Fauser Journal: Lancet Date: 2007-03-03 Impact factor: 79.321
Authors: M Brandes; J O M van der Steen; S B Bokdam; C J C M Hamilton; J P de Bruin; W L D M Nelen; J A M Kremer Journal: Hum Reprod Date: 2009-09-26 Impact factor: 6.918
Authors: C Blockeel; N P Polyzos; L Derksen; M De Brucker; V Vloeberghs; A van de Vijver; M De Vos; H Tournaye Journal: Hum Reprod Date: 2014-05-09 Impact factor: 6.918
Authors: M F G Verberg; N S Macklon; G Nargund; R Frydman; P Devroey; F J Broekmans; B C J M Fauser Journal: Hum Reprod Update Date: 2009 Jan-Feb Impact factor: 15.610
Authors: Anderson Sanches de Melo; Camilla Teles Vidal de Paula; Thiago Lopes Dos Santos; Victor Antonio Costa Faria; Marcelo Augusto Feres Rufato; Rebecca Pontelo Barboza; Jorge Barreto Journal: JBRA Assist Reprod Date: 2022-04-17